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Background: Correlation of plasma fibrinogen concentration (fibrinogenClauss) with rotational
thromboelastometry (ROTEM) parameters has not been investigated in dogs.
Objectives: To determine the correlation between plasma coagulation tests and fibrinogenClauss
with ROTEM parameters and to evaluate their ability to predict bleeding in dogs.
Animals: Ninety-seven dogs with concurrent determination of fibrinogenClauss and fibrin poly-
merization test (FIBTEM) analysis.
Methods: Signalment, pretreatment, clinical signs of bleeding, fibrinogenClauss, plasma coagula-
tion test results, hematocrit, platelet count, FIBTEM, extrinsic (EXTEM) and intrinsic (INTEM)
activated ROTEM assays were retrieved retrospectively. Correlations between fibrinogenClauss
and FIBTEM maximum clot firmness (MCFFIBTEM) and between prothrombin time (PT) or
activated partial thromboplastin time (aPTT) and ROTEM parameters were determined. Dogs
were further assigned to groups with or without clinical signs of bleeding. The prognostic signifi-
cance of significantly different parameters to predict bleeding was evaluated.
Results: FibrinogenClauss showed strong correlation with MCFFIBTEM (r = 0.860, n = 97, P < .001).
PT showed strong correlation with EXTEM clotting time (CTEXTEM) (r = 0.839, n = 53, P < .001),
and aPTT was strongly correlated with INTEM CT (CTINTEM) (r = 0.664, n = 31, P < .001). Platelet
count, PT/aPTT, EXTEM clot formation time (CFTEXTEM), MCFEXTEM, EXTEM maximum clot
elasticity (MCEEXTEM), and CTINTEM were significantly different between groups. A CTINTEM
>149 seconds was 100% sensitive to detect bleeding.
Conclusions and Clinical Importance: The MCFFIBTEM can be used to evaluate the effect of fibrin-
ogen on hemostasis as an alternative to determination of fibrinogenClauss. In addition, CTEXTEM and
CTINTEM are strongly correlated with PT and aPTT, respectively.
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1 | INTRODUCTION
Fibrinogen plays a key role in forming a stable and impermeable clot at
the site of tissue damage.1,2 The linking of fibrinogen to activated
platelets is followed by cleavage of fibrinogen to fibrin and its polymeri-
zation.1,3 Fibrinogen is the 1st factor to become critically decreased
during dilutional coagulopathy and perioperative hemorrhage.2,4,5 Early
recognition of coagulopathy because of hypofibrinogenemia is
Abbreviations: aPTT, activated partial thromboplastin time; AUC, area under
the curve; CFT, clot formation time; CT, clotting time; EXTEM, extrinsic-
activated ROTEM; Fc, fibrinogen measured by the Clauss method; FIBTEM,
fibrin polymerization test; INTEM, intrinsic-activated ROTEM; MCE, maximum
clot elasticity; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrom-
bin time; ROC, receiver operating characteristics; ROTEM, rotational
thromboelastometry.
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important because it is potentially reversible and correction may
improve outcome.6,7
Various methods are used to determine plasma fibrinogen concen-
tration, such as the Clauss method, antigen determination, and
viscoelastic measurements by means of thromboelastometry.8,9 Cur-
rently, the most commonly used assay is the fibrinogen Clauss assay
(Fc), where a high concentration of thrombin is added to diluted citrated
plasma followed by measurement of the clotting time (CT).9–12 The CT
of fibrinogen is measured by mechanical or photo-optical principles. The
mechanical method identifies dissociation of a metal ball from a mag-
netic field upon clot formation, whereas the photo-optical method
records alteration in turbidity.12 In the mechanical method, time mea-
surement is started after the addition of thrombin reagent to the plasma
sample and is stopped when the contact of a steel ball and a magnetic
sensor is broken because of its incorporation into the fibrin network.13
A predetermined standard curve of CT against fibrinogen concentration
is used to read Fc, which is inversely correlated with CT.12,14
Several studies have documented that standard coagulation tests
are time-consuming and not effective to identify patients with increased
risk of bleeding.7,15–17 Rotational thromboelastometry (ROTEM) allows a
preliminary evaluation of coagulation within 10 minutes, compared to
the 45-60 minutes for plasma coagulation assays, enabling effective
implementation of therapeutic interventions.10,18,19 The extrinsic-
activated ROTEM (EXTEM) assay is activated by proprietary tissue fac-
tor, whereas the intrinsic-activated ROTEM (INTEM) assay is activated
by ellagic acid and phospholipid. The fibrin polymerization test (FIBTEM)
is an EXTEM-based assay with the addition of cytochalasin D to inacti-
vate the platelets.20 The FIBTEM assay indicates the formation and sta-
bility of the fibrin clot.21 In people, FIBTEM maximum clot firmness
(MCFFIBTEM) is used as a parameter representing the functional whole-
blood fibrinogen concentration.3,11,18
Correlation of Fc and MCFFIBTEM has been investigated in people
and cats but not in dogs.3,7,10,19,22–24 The correlation of other throm-
boelastometry parameters and plasma coagulation tests has been inves-
tigated in clinically healthy dogs, showing only moderate correlation.25
The purpose of our study was to determine correlations between Fc
and MCFFIBTEM and between the plasmatic coagulation tests prothrom-
bin time (PT) and activated partial thromboplastin time (aPTT) with
ROTEM parameters in a population of healthy and sick dogs and to
identify factors that influence this correlation. Our hypothesis was that
a correlation exists between Fc and plasma coagulation times and
ROTEM parameters. Furthermore, the ability of plasma coagulation
tests and ROTEM parameters to predict bleeding in dogs was
evaluated.
2 | MATERIALS AND METHODS
2.1 | Data collection and classification
The hospital's patient and laboratory databases were searched for
ROTEM analysis and Fc determination in dogs between 2013 and
2017. Eligible dogs were of any breed, either sex, and older than
0.5 years. Medical records of identified dogs were checked for simul-
taneous measurements of Fc and MCFFIBTEM.
Signalment, treatment before analysis (eg, fluid treatment,
transfusions, drugs within 3 days before fibrinogen measurement),
hematocrit, platelet count, PT, aPTT, Fc, EXTEM-S (EXTEM assay with
single-use reagent), INTEM-S (INTEM assay with single-use reagent),
and FIBTEM-S (FIBTEM assay with single-use reagent) parameters
(CT, measured in seconds; clot formation time [CFT], measured in
seconds; MCF, measured in millimeter; and maximum lysis [ML],
measured in percentage) were extracted from patient records and
included if measurements had been made simultaneously. Fc, PT, and
aPTT were determined using a semiautomatic mechanical method
(STAGO CH SA, Zurich, Switzerland). The ROTEM-S (ROTEM-Delta;
single-use reagent TEM Innovations GmbH, Munich, Germany) analysis
was performed following an institutional standard operating protocol
based on manufacturer's instructions and international guidelines.26–29
Briefly, 300 μL citrated blood was allowed to stand for approximately
10 minutes in the 37C warming chamber of the device followed by
analysis using an automated pipette and single portion reagents.
Samples were analyzed for 60 minutes. The ROTEM tracings were
evaluated visually for artifacts and excluded if suspicious. If several
measurements of 1 dog were present, the 1st measurement
was used.
Based on patient records, dogs were classified as with or without
clinical signs of bleeding (bleeding versus non-bleeding group). Bleeding
was defined as any visible external bleeding including tissue bleeding,
epistaxis, hemoptysis, hematochezia, melena, petechiae or ecchymosis,
identification of hemoabdomen or hemothorax (effusion hematocrit
>20% or intraoperative diagnosis), or pulmonary or central nervous sys-
tem changes suspicious for bleeding based on diagnostic imaging (head
computed tomography, chest radiographs) together with clinical results
and diagnosis. In addition, dogs were classified as hypocoagulable if ≥2
results of the following ROTEM parameters were indicative of hypocoa-
gulability based on institutional reference intervals: MCFEXTEM < 32 mm,
MCFFIBTEM < 2 mm, CTEXTEM > 87, and CFTEXTEM > 357 seconds.
30
Hypercoagulability was defined as a decrease in CTEXTEM (<23 seconds)
or CFTEXTEM (<85 seconds) or an increase in MCFEXTEM (>65 mm)
or a combination of these parameters.31 For statistical analysis, an
undetectable MCFFIBTEM, identified as a green line, was defined as
MCFFIBTEM = 1 mm. If MCFEXTEM did not reach the amplitude of
20 mm, CFTEXTEM was defined as 3600 seconds (ie, run time of
ROTEM). The definition of hyperfibrinolysis was based on an ML value
exceeding the upper reference value of 14%.
2.2 | Data analyses and statistics
Data were manually entered or copied (ROTEM parameters) into a
spreadsheet. Statistical analyses were performed using the statistical
software package SPSS (IBM SPSS statistics 25.0, Armonk, NY, USA).
Continuous data were tested for normality using the Shapiro-Wilk
test. Depending on the underlying distribution, data were expressed
as mean and SD or median and range. Nonparametrically distributed
continuous variables were compared using the Mann-Whitney U test.
A Student's t test was performed to detect differences between
patient groups with parametrically distributed continuous variables.
The chi-square test was used to evaluate the associations between
categorical variables. Correlation of parametric data was assessed
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using the Pearson method. For nonparametrically distributed data,
Spearman's correlation was used for analysis. The accuracy of stan-
dard coagulation tests and ROTEM to determine dogs with clinical
sings of bleeding was evaluated using receiver operating characteris-
tics (ROC) and the area under the ROC curve (AUC). You den's J sta-
tistic was used to select the optimum cutoff point of the ROC curves.
A P-value <.05 was considered statistically significant.
3 | RESULTS
The database search identified 108 dogs with concurrent ROTEM and
Fc analysis. Nine dogs were subsequently excluded because of lack of
simultaneous measurements of Fc and MCFFIBTEM. Two dogs were
excluded because ROTEM analysis showed artifacts. Therefore,
97 dogs met the inclusion criteria and were enrolled. The study popu-
lation included 41 different breeds with Beagles (16.5%), crossbreeds
(15.5%), Flat Coated Retrievers (7.2%), and Golden Retrievers (6.2%)
being the most common. Sixty-one dogs (62.9%) were female
(27 intact, 34 spayed) and 36 (37.1%) dogs were male (27 intact, 9 cas-
trated). Median age was 4.8 years (range, 0.5-14.9 years) and median
weight was 18.0 kg (range, 2.2-60.0 kg). Nonsteroidal anti-
inflammatory drugs (NSAIDs) had been administered to 8 of 97 dogs
(8.2%); of the 97 dogs, 8 (8.2%) had received synthetic vitamin K,
5 (5.2%) had received tranexamic acid, 3 (3.1%) had been treated with
fresh frozen plasma, and 2 (2.1%) had received a whole-blood transfu-
sion within 3 days before blood sampling. Forty-seven (48.5%) dogs
were considered healthy based on clinical examination and blood anal-
ysis results. The remaining 50 (51.5%) dogs had been presented with
various diseases.
Of the 66 dogs with an available EXTEM analysis, 25 (37.9%)
were defined as hypocoagulable and 8 (12.1%) were defined as
hypercoagulable. Nineteen of 97 dogs (19.6%) had Fc below, and
20 of the 97 (20.6%) dogs had Fc above the reference interval
(1.2-2.8 g/L), whereas MCFFIBTEM was <2 mm (green line) in 17 of the
97 dogs (17.5%; Figure 1). Nine of 66 (13.6%) dogs were considered
hyperfibrinolytic.
Correlations among ROTEM parameters, Fc, and plasma coagula-
tion times including subgroup analysis are summarized in Table 1.
FibrinogenClauss was strongly correlated with MCFFIBTEM (r = 0.860,
P < .001; Figure 1). PT was strongly correlated with CTEXTEM
(r = 0.839, P < .001) and strongly correlated with CFTEXTEM (r = 0.695,
P < .001; Table 1 and Figure 2). For aPTT, the best correlation was
found between CTINTEM and aPTT (r = 0.664, P < .001; Table 1 and
Figure 3).
Mean or median ROTEM parameters generated with EXTEM-S,
INTEM-S, and FIBTEM-S analysis, and available hematology and coag-
ulation parameters are presented in Table 2. Thirty of 96 dogs (30.9%)
had clinical signs of bleeding (bleeding group) with 15 of these (50.0%)
being considered hypocoagulable and 13 dogs (43.3%) being thrombo-
cytopenic. Platelet count, PT, aPTT, and the ROTEM parameters
including CFTEXTEM, MCFEXTEM, and CTINTEM were significantly differ-
ent between dogs with and without clinical signs of bleeding (Table 2).
The specific parameters and their cutoff values for detecting dogs
with clinical signs of bleeding analyzed with ROC are shown in
Table 3. The definition of hypocoagulability used showed a sensitivity
of 60% and a specificity of 65% to detect bleeding (P = .04).
4 | DISCUSSION
Ours is the 1st study to report a strong correlation between Fc and
MCFFIBTEM in dogs. PT and aPTT also strongly correlated with CTEXTEM
and CTINTEM, respectively.
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FIGURE 1 Scatter plot showing the correlation between fibrinogenClauss and MCFFIBTEM in 113 dogs. Linear adjustment is marked. Circles in red
and triangles in blue represent dogs with and without clinical signs of bleeding, respectively. Abbreviations: FIBTEM, fibrin polymerization test;
MCF, maximum clot firmness; n, number of variables; r, correlation coefficient
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Similarly, strong correlations between Fc and FIBTEMMCF have
been reported in people.3,7,10,22–24,32 Compared with the correlation
between Fc and MCFFIBTEM in healthy cats (r = 0.620; P = .001),
19 a
stronger correlation was found in our population of both healthy and
clinically ill dogs. Including abnormal results, both below and above
the reference interval generally leads to a stronger correlation than
when all results are distributed in a narrow range, assuming that the
2 parameters are correlated. A correlation between Fc and MCFFIBTEM
is expected, because both methods assess fibrinogen cleavage to
fibrin. However, they differ in terms of the examined sample (diluted
serum versus whole blood with cytochalasin D–inactivated platelets),
activator (high dose of thrombin versus tissue factor), end point
determination (1st change in mobility of a metal ball in a magnetic
field versus changes in mobility of an oscillating pin), and output
(CT [seconds] proportional to predetermined fibrinogen concentration
[g/L] versus maximal clot firmness in millimeters).11–13,33
Discrepancies in correlation may be explained by the different
end points that are measured by the 2 methods. Although the fibrino-
gen concentration is the major determinant of MCFFIBTEM, it also
depends on the availability of factor XIII34,35 and involves the activity
of coagulation factors of the extrinsic pathway, functional fibrinogen,
and erythrocytes, and therefore evaluates additional effects of blood
cellular components on clot strength.36–38 Importantly, although the
method of Clauss estimates fibrinogen concentration based on CT,
TABLE 1 Correlation (r) between plasmatic coagulation tests and ROTEM parameters in dogs and divisions into subgroups
Fc and MCFFIBTEM PT and CTEXTEM aPTT and CTINTEM
n/N/% r P n/N/% r P n/N/% r P
All values 97/97/100 0.860 .001 53/53/100 0.839 .001 31/31/100 0.664 .001
Hematocrit
<40% 30/95/31.6 0.940 <.001 22/52/42.3 0.921 <.001 10/31/32.3 0.491 .15
≥40% 65/95/68.4 0.749 <.001 30/52/57.7 0.712 <.001 21/31/67.7 0.035 .88
Platelet count
<130 (×106/μL) 20/87/23.0 0.855 <.001 17/48/35.4 0.937 <.001 24/29/82.8 0.392 .05
≥130 (×106/μL) 67/87/77.0 0.802 <.001 31/48/64.6 0.602 <.001 5/29/17.2 0.500 .39
Hyperfibrinolysis
MLEXTEM > 14% 9/66/13.6 0.980 <.001 7/53/13.2 0.964 <.001 1/30/3.3 (−) (−)
MLEXTEM < 14% 57/66/86.4 0.865 <.001 46/53/86.8 0.764 <.001 29/30/96.7 0.391 .03
Pretreatment
Yes 19/95/20.0 0.913 <.001 12/51/23.5 0.930 <.001 3/31/9.7 1.000 (−)
No 76/95/80.0 0.840 <.001 39/51/76.5 0.759 <.001 28/31/90.3 0.256 .18
Abbreviations: aPTT, activated partial thromboplastin time; CT, clotting time; EXTEM, extrinsic-activated ROTEM; Fc, fibrinogen measured by the Clauss
method; FIBTEM, fibrin polymerization test; INTEM, intrinsic-activated ROTEM; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time;
ROTEM, rotational thromboelastometry; (−), no data available.
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FIGURE 2 Correlation between PT and CTEXTEM in 53 dogs. Linear adjustment is marked. Circles in red and triangles in blue represent dogs with
and without clinical signs of bleeding, respectively. Abbreviations: CT, clotting time; EXTEM, extrinsic-activated rotational thromboelastometry; n,
number of variables; PT, prothrombin time; r, correlation coefficient
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the FIBTEM-S assay does not provide a fibrinogen concentration but
visualizes the clot that forms from cross-linked fibrin strands, erythro-
cytes, and factor XIII.36 In contrast to fibrinogen determined by the
Clauss method, MCFFIBTEM represents a stable clot and requires func-
tional fibrinogen that is not only cleaved to fibrin polymers but also
cross-linked.11 The FIBTEM-S assay further provides additional infor-
mation regarding the clot strength and clot lysis.33 The MCFFIBTEM
therefore is believed to predict the function of fibrinogen better
rather than Fc and is increasingly used for guidance of fibrinogen
treatment in people.37,39,40
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FIGURE 3 Correlation between aPTT and CTINTEM in 31 dogs. Linear adjustment is marked. Circles in red and triangles in blue represent dogs
with and without clinical signs of bleeding, respectively. Abbreviations: aPTT, activated partial thromboplastin time; CT, clotting time; INTEM,
intrinsic-activated rotational thromboelastometry; n, number of variables; r, correlation coefficient
TABLE 2 Descriptive statistics and comparison between dogs with and without clinical signs of bleeding
Parameter (unit) Reference interval Total population (n = 97) Non-bleeding group (n = 66) Bleeding group (n = 30) P-value
Hematology
Hematocrit (%) 40-55 44 (16-60) [95] 46 (18-60) [65] 36  9 [29] .001
Platelet count (×106/μL) 130-394 225  115 [87] 256  104 [61] 146  106 [25] .001
Standard coagulation tests
Fc (g/L) 1.2-2.9 1.9 (0.1-8.5) [97] 1.9 (0.1-8.5) [66] 1.9 (0.1-7.5) [30] .39
PT (s) 6.5-8.7 7.5 (6.4-24.4) [83] 7.4 (6.5-11.7) [58] 8.8 (6.4-24.4) [24] .004
aPTT (s) 10.3-13.8 12.2 (8.9-200.0) [83] 11.9 (8.9-19.0) [58] 15.7 (11.1-200.0) [24] .001
EXTEM-S assay
CTEXTEM (s) 23-87 44 (22-1201) [66] 41 (22-159) [36] 45 (22-1201) [29] .28
CFTEXTEM (s) 85-357 210 (22-3600) [65] 153 (23-2935) [36] 313 (22-3600) [28] .04
MCFEXTEM (mm) 32-65 45  18 [66] 50  15 [36] 40  17 [29] .01
MLEXTEM (%) 0-12 2 (0-100) [66] 1 (0-30) [36] 2 (0-100) [29] .06
INTEM-S assay
CTINTEM (s) 133-210 157  31 [32] 149  31 [24] 190  46 [7] .01
CFTINTEM (s) 59-201 71 (35-551) [32] 66 (35-520) [24] 82 (35-551) [7] .25
MCFINTEM (mm) 52-71 64 (32-83) [32] 64 (32-80) [24] 58  18 [7] .87
FIBTEM-S assay
MCFFIBTEM (mm) 2-9 5 (1-31) [97] 5 (1-25) [66] 5 (1-31) [30] .34
Abbreviations: aPTT, activated partial thromboplastin time; CFT, clot formation time; CT, clotting time; EXTEM, extrinsic-activated rotational thromboelas-
tometry; Fc, fibrinogen measured by the Clauss method; FIBTEM, fibrin polymerization test; INTEM, intrinsic-activated rotational thromboelastometry;
MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time.
Number of variables within a subgroup is shown in square brackets.
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An additional explanation for decreased correlation may be a
residual platelet effect on MCFFIBTEM that becomes more important
the more hypofibrinogenemic a patient becomes.21 In addition, ane-
mia may lead to a hypercoagulable FIBTEM tracing because of higher
concentrations of coagulation factors in a whole-blood sample with a
decreased hematocrit, whereas Fc is not affected by hematocrit.25,41
In our study, correlation of Fc with MCFFIBTEM was higher in blood
samples with a hematocrit below the reference interval. In contrast to
Fc, MCFFIBTEM depends on hematocrit
42 and an effect on correlation
with changes in hematocrit is expected. Both correlations were
assessed as strong to very strong; therefore, the clinical importance of
hematocrit changes remains to be determined.
Of note, some dogs with Fc within the reference interval did not
show clotting in the FIBTEM-S analysis (green line). Again, this observa-
tion can be explained by the different measurement end points and
implies that fibrinogen is present and to some degree functional, but a
stable clot cannot be formed. The addition of thrombin in excess
(as used in the Clauss method) to some extent overcomes inhibiting fac-
tors of clot generation that may lead to a decrease in MCFFIBTEM.
11,43
In these cases, the fibrinogen concentration is overestimated by the
Clauss method in relation to MCFFIBTEM.
11,43
Other reasons for a lack of correlation are test interference by
dysfunctional fibrinogen protein in the blood sample, hyperfibrinolysis
of circulating fibrin, or a deficiency of factor XIII.10,44–46 During fibri-
nolytic treatment or in hyperfibrinolytic conditions, fibrin or fibrinogen
degradation products inhibit fibrin polymerization, leading to a rela-
tively low fibrinogen concentration as measured by the Clauss
method.47–49 However, MCFFIBTEM theoretically also should be
blunted by fibrin degradation products, and the correlation in hyperfi-
brinolytic dogs was better than in the whole population. Fibrinogen
degradation products were not measured in our study, and because
dogs with hyperfibrinolysis showed an even stronger correlation of Fc
with MCFFIBTEM, hyperfibrinolysis as a cause of the low MCFFIBTEM
compared to normal Fc concentration seems unlikely. However,
because of the low number of dogs experiencing hyperfibrinolysis, we
believe that this result should be interpreted with caution. Overall,
MCFFIBTEM can be used in dogs to approximate the plasma fibrinogen
concentration and function as described in people and in cats.19,21
We also found a very strong correlation between CTEXTEM and PT
and a strong correlation between aPTT and CTINTEM. The identified
correlations are stronger than previously described in healthy dogs.25
Again, this finding can be explained by the fact that correlations
become stronger when more diverse results are included in the analy-
sis. A correlation between PT and aPTT with CTEXTEM or CTINTEM is
expected despite different measurement methods of CT. Both
plasma-based coagulation tests and ROTEM CT evaluate the activity
of soluble coagulation factors. Prothrombin time measures the time it
takes for plasma to clot after addition of thromboplastin and calcium
ions. Time measurement stops when the small metal ball of the device
gets out of an electromagnetic field because of fibrin fiber formation.
The measuring method of aPTT is identical; but instead of thrombo-
plastin, phospholipids are added.50 At that time, approximately 5% of
the total thrombin has been generated.51 In contrast, CTEXTEM/INTEM
represents the time from activation of the extrinsic pathway by tissue
factor or ellagic acid to the start of clot building in a whole-blood sam-
ple and evaluates the initiation phase of thrombin generation.52 Nota-
bly, CT is measured in whole blood and involves interaction with
platelets and red blood cells. Again, the presence of red blood cells is
expected to influence viscoelastic coagulation test results25 and
explain some of the discrepancies in correlation.
The comparison of dogs with and without clinical signs of bleed-
ing and possible anticipation of probability to bleed based on coagula-
tion parameters including ROTEM parameters was an additional aim
of our study. Hematocrit and platelet count were lower in dogs with
bleeding compared to dogs in the non-bleeding group.
The significantly lower hematocrit was attributed to hemorrhage,
but we cannot exclude other reasons for anemia. Although the mean
platelet count was significantly lower in the bleeding group, both
groups had platelet counts within the reference interval, implying that
the lower platelet count was not the main reason for bleeding. In con-
trast, the median standard plasma coagulation tests PT and aPTT were
both significantly prolonged in bleeding dogs and above the reference
interval in 50% of the bleeding dogs. Prolongations in PT and aPTT
can be the cause or result of bleeding, and neither of the parameters
showed good sensitivity for the detection of bleeding. However,
TABLE 3 Parameters for detecting dogs with clinical signs of bleeding analyzed with ROC
Parameter n Cutoff value Sensitivity (%) Specificity (%) AUC P-value
Platelet count (×106/μL) 86 196 76.0 77.0 0.775 .001
Fc (g/L) 96 0.95 36.7 93.9 0.554 .39
PT (s) 82 10.6 45.8 96.6 0.705 .004
aPTT (s) 82 16.25 50.0 96.6 0.767 .001
CTEXTEM (s) 65 133 34.5 97.2 0.577 .28
CFTEXTEM (s) 64 221 67.9 63.9 0.650 .04
MCFEXTEM (mm) 65 51 75.9 61.1 0.685 .01
CTINTEM (s) 32 149 100.0 50.0 0.789 .02
CFTINTEM (s) 32 68 85.7 54.2 0.646 .24
MCFINTEM (mm) 32 37 28.6 95.8 0.524 .85
MCFFIBTEM (mm) 96 2.5 40.0 87.9 0.560 .34
Abbreviations: aPTT, activated partial thromboplastin time; AUC, area under the curve; CFT, clot formation time; CT, clotting time; EXTEM,
extrinsic-activated rotational thromboelastometry; Fc, fibrinogen measured by the Clauss method; FIBTEM, fibrin polymerization test; INTEM,
intrinsic-activated rotational thromboelastometry; MCF, maximum clot firmness; PT, prothrombin time; ROC, receiver operating characteristics.
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specificity was high, indicating that patients with PT and aPTT within
the reverence interval are unlikely to bleed.
Because viscoelastic tests involve interaction of coagulation fac-
tors with platelets, they are expected to be superior in identifying a
bleeding tendency in patients with complex hemostatic disorders.
However, although the ROTEM parameters CFTEXTEM, MCFEXTEM, and
CTINTEM were significantly different between bleeding and non-
bleeding dogs, many bleeding dogs had results within the reference
intervals. Although the specificity to exclude bleeding if parameters
were within the reference interval was reasonably high, the sensitivity
to detect bleeding was low. However, CTINTEM >149 seconds was
100% sensitive to detect bleeding, despite a specificity of 50%. Few
studies have focused on prediction of bleeding by use of viscoelastic
coagulation assays in dogs.53,54 In a previous study, investigators dem-
onstrated that tissue factor-activated thromboelastography, the ana-
logue of EXTEM, correctly identified dogs with clinical signs of
bleeding.53 Although the ROC curve of MCFEXTEM showed a high AUC
(0.685) in our population, MCFEXTEM does not seem to be a clinically
useful individual parameter because of low sensitivity and specificity.
Because bleeding can be caused by the lack or deficiency of any
factor or mechanism of hemostasis, it seems prudent that in a hetero-
geneous population of dogs with bleeding, a single parameter is not
helpful to predict bleeding. Because ROTEM allows examination of
many aspects of hemostasis in whole blood, a combination of ROTEM
parameters, which evaluate the different steps of hemostasis, is
expected to be superior to predict bleeding. However, the definition
of hypocoagulability used in our study, as well as in previous
studies,30,31,55,56 did not identify a useful sensitivity to predict bleed-
ing. We suspect that a more complex scoring system is needed to pre-
dict bleeding in dogs, similar to that described in people.57
Being retrospective in nature, our study has several limitations.
Dogs were included if they had concurrent Fc and FIBTEM analysis and
standard coagulation tests, and EXTEM and INTEM assays were
not additionally available for all dogs. Subgroup analysis and the
CTINTEM/aPTT correlation therefore should be interpreted with
caution and requires larger studies to identify confounding factors.
Furthermore, because we examined a heterogeneous population of
clinically ill dogs, some dogs were pretreated with fluids or other
medications, including NSAIDs, which may have had an effect on the
test results. Because correlation was improved when pretreated
patients were compared to untreated dogs, we believe this effect is
negligible and potentially affected both tests. Additional studies are
needed to evaluate the impact of confounding factors in more detail.
As a 3rd limitation, our diagnosis of bleeding was based on clinical
signs and we therefore cannot make any statement regarding bleed-
ing that was not clinically apparent.
In conclusion, MCFFIBTEM can be used to evaluate the effect of
plasma fibrinogen on hemostasis as an alternative to determination of
Fc. In addition, CTEXTEM and CTINTEM were strongly correlated with
PT and aPTT, respectively, and can be used to assess the extrinsic and
intrinsic pathways of clot formation. None of the assessed parameters
could predict bleeding with both high sensitivity and high specificity.
However, CTINTEM >149 seconds was 100% sensitive to detect bleed-
ing therefore could be used more frequently for identification of coag-
ulation disorders in the future.
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